Abliva AB (publ) Stock Forecast, Price & News

-0.02 (-15.59 %)
(As of 06/17/2021 09:37 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume200 shs
Average Volume7,641 shs
Market Capitalization$25.27 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive NEVPF News and Ratings via Email

Sign-up to receive the latest news and ratings for Abliva AB (publ) and its competitors with MarketBeat's FREE daily newsletter.

Abliva AB (publ) logo

About Abliva AB (publ)

Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.50 out of 5 stars

Medical Sector

1657th out of 2,100 stocks

Pharmaceutical Preparations Industry

715th out of 831 stocks

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Abliva AB (publ) (OTCMKTS:NEVPF) Frequently Asked Questions

What stocks does MarketBeat like better than Abliva AB (publ)?

Wall Street analysts have given Abliva AB (publ) a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Abliva AB (publ) wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Abliva AB (publ)?

Abliva AB (publ) saw a increase in short interest in the month of May. As of May 14th, there was short interest totaling 25,000 shares, an increase of 67.8% from the April 29th total of 14,900 shares. Based on an average daily volume of 30,900 shares, the short-interest ratio is presently 0.8 days.
View Abliva AB (publ)'s Short Interest

When is Abliva AB (publ)'s next earnings date?

Abliva AB (publ) is scheduled to release its next quarterly earnings announcement on Wednesday, June 23rd 2021.
View our earnings forecast for Abliva AB (publ)

How has Abliva AB (publ)'s stock been impacted by Coronavirus?

Abliva AB (publ)'s stock was trading at $0.0796 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NEVPF shares have increased by 17.7% and is now trading at $0.0937.
View which stocks have been most impacted by COVID-19

Who are Abliva AB (publ)'s key executives?

Abliva AB (publ)'s management team includes the following people:
  • Dr. Ellen K. Donnelly, Chief Exec. Officer (Age 47)
  • Ms. Catharina Jz Johansson, Deputy CEO, CFO & VP of Investor Relations (Age 54)
  • Dr. Eskil Elmér, Chief Scientific Officer & VP of Discovery (Age 51)
  • Daniel Schale, Director of Communications
  • Dr. Magnus Hansson, Chief Medical Officer and VP of Preclinical & Clinical Devel. (Age 45)
  • Dr. Lars Vedin, Consultant

Who are some of Abliva AB (publ)'s key competitors?

What is Abliva AB (publ)'s stock symbol?

Abliva AB (publ) trades on the OTCMKTS under the ticker symbol "NEVPF."

How do I buy shares of Abliva AB (publ)?

Shares of NEVPF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Abliva AB (publ)'s stock price today?

One share of NEVPF stock can currently be purchased for approximately $0.09.

How much money does Abliva AB (publ) make?

Abliva AB (publ) has a market capitalization of $25.27 million and generates $10,000.00 in revenue each year.

How many employees does Abliva AB (publ) have?

Abliva AB (publ) employs 7 workers across the globe.

What is Abliva AB (publ)'s official website?

The official website for Abliva AB (publ) is www.neurovive.com.

Where are Abliva AB (publ)'s headquarters?

Abliva AB (publ) is headquartered at MEDICON VILLAGE SCHEELEVAGEN 2, LUND V7, 22381.

How can I contact Abliva AB (publ)?

Abliva AB (publ)'s mailing address is MEDICON VILLAGE SCHEELEVAGEN 2, LUND V7, 22381. The company can be reached via phone at 46-4-627-562-20 or via email at [email protected]

This page was last updated on 6/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.